← Back to Search

Monoclonal Antibodies

ATRC-101 for Cancer

Phase 1
Waitlist Available
Research Sponsored by Atreca, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests ATRC-101, a specially designed antibody, in adults with advanced cancers that haven't responded well to other treatments. ATRC-101 helps the immune system find and attack cancer cells. ATRC-101 has shown strong antitumor activity and evidence of immune memory in early studies.

Who is the study for?
Adults with certain advanced cancers (like breast, lung, colorectal, ovarian cancer or melanoma) that can't be removed by surgery or have spread and don't respond to standard treatments. They must have measurable disease and adequate organ function. Women who can bear children and men with partners of this potential must use effective birth control.
What is being tested?
ATRC-101 is being tested alone or with other cancer drugs (Pembrolizumab/PLD). This trial checks its safety, how the body handles it, and if it works against cancer when given every 2 or 3 weeks. It's an early-phase study where everyone gets the experimental treatment.
What are the potential side effects?
Possible side effects include reactions related to the immune system affecting organs, infusion-related reactions which could happen during drug administration, fatigue, blood disorders like changes in cell counts leading to increased infection risk.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: ATRC-101 Q3W + PembrolizumabExperimental Treatment2 Interventions
Pembrolizumab 200mg IV Q3W or 400mg IV Q6W
Group II: ATRC-101 Q3WExperimental Treatment1 Intervention
Group III: ATRC-101 Q2W + Pegylated liposomal doxorubicin (PLD)Experimental Treatment2 Interventions
PLD 40mg/m\^2 IV Run-in period of 28 days, and then 40mg/m\^2 IV Q4W
Group IV: ATRC-101 Q2WExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~3130
Pegylated liposomal doxorubicin (PLD)
2015
Completed Phase 3
~1060

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for colorectal cancer include immunotherapy and targeted therapies. Immunotherapy, such as immune checkpoint inhibitors, works by enhancing the body's immune response against cancer cells. These inhibitors block proteins like PD-1/PD-L1, which cancer cells use to evade the immune system. Targeted therapies, such as monoclonal antibodies, specifically target cancer cell antigens or pathways critical for tumor growth and survival. For example, cetuximab targets the epidermal growth factor receptor (EGFR) on cancer cells, inhibiting their growth. These treatments are crucial for colorectal cancer patients as they offer more personalized and effective options, especially for those who do not respond to traditional chemotherapy.

Find a Location

Who is running the clinical trial?

Atreca, Inc.Lead Sponsor
Jonathan Benjamin, MD, PhDStudy DirectorAtreca, Inc.
Sudha Khurana, PhDStudy DirectorAtreca, Inc.

Media Library

ATRC-101 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04244552 — Phase 1
Esophageal Carcinoma Research Study Groups: ATRC-101 Q3W, ATRC-101 Q2W + Pegylated liposomal doxorubicin (PLD), ATRC-101 Q2W, ATRC-101 Q3W + Pembrolizumab
Esophageal Carcinoma Clinical Trial 2023: ATRC-101 Highlights & Side Effects. Trial Name: NCT04244552 — Phase 1
ATRC-101 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04244552 — Phase 1
Esophageal Carcinoma Patient Testimony for trial: Trial Name: NCT04244552 — Phase 1
~15 spots leftby Dec 2025